BR112020018585A8 - Uso de mimeticos de restrição calórica para potencializar a quimioimunoterapia para o tratamento de câncer - Google Patents
Uso de mimeticos de restrição calórica para potencializar a quimioimunoterapia para o tratamento de câncerInfo
- Publication number
- BR112020018585A8 BR112020018585A8 BR112020018585A BR112020018585A BR112020018585A8 BR 112020018585 A8 BR112020018585 A8 BR 112020018585A8 BR 112020018585 A BR112020018585 A BR 112020018585A BR 112020018585 A BR112020018585 A BR 112020018585A BR 112020018585 A8 BR112020018585 A8 BR 112020018585A8
- Authority
- BR
- Brazil
- Prior art keywords
- crms
- cancer
- chemoimmunotherapy
- caloric restriction
- enhance
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
USO DE MIMETICOS DE RESTRIÇÃO CALÓRICA PARA POTENCIALIZAR A QUIMIOIMUNOTERAPIA PARA O TRATAMENTO DE CÂNCER . Na maioria dos casos, a quimioterapia e a imunoterapia contra o câncer não produzem respostas duráveis e a regressão completa e permanente dos tumores estabelecidos é rara. Aqui, os inventores mostram que os chamados miméticos de restrição calórica (CRMs), que são compostos naturais ou sintéticos que mimetizam farmacologicamente os efeitos do jejum ou da restrição calórica, podem ser usados para aumentar a probabilidade de cura do câncer. A administração de vários CRMs quimicamente distintos (como hidroxicitrato, ácido lipoico e a espermidina poliamina natural) levou à regressão completa e à indução de respostas imunológicas de proteção anticancerígenas em modelos de camundongos. Este efeito foi alcançado quando CRMs foram combinados com quimioterapia e imunoterapia tendo como alvo as moléculas de ponto de verificação imunológico CTLA-4 e/ou PD-1. Portanto, a restrição calórica e os CRMs podem ser usados para sensibilizar os cânceres à quimioimunoterapia.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18305257 | 2018-03-12 | ||
EP18305257.0 | 2018-03-12 | ||
EP18305359.4 | 2018-03-29 | ||
EP18305359 | 2018-03-29 | ||
PCT/EP2019/056041 WO2019175113A1 (en) | 2018-03-12 | 2019-03-11 | Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112020018585A2 BR112020018585A2 (pt) | 2020-12-29 |
BR112020018585A8 true BR112020018585A8 (pt) | 2022-12-06 |
Family
ID=66102028
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112020018585A BR112020018585A8 (pt) | 2018-03-12 | 2019-03-11 | Uso de mimeticos de restrição calórica para potencializar a quimioimunoterapia para o tratamento de câncer |
Country Status (11)
Country | Link |
---|---|
US (1) | US20210030703A1 (pt) |
EP (1) | EP3765085A1 (pt) |
JP (1) | JP2021517589A (pt) |
KR (1) | KR20210004966A (pt) |
CN (1) | CN112218658A (pt) |
AU (1) | AU2019236402A1 (pt) |
BR (1) | BR112020018585A8 (pt) |
CA (1) | CA3093742A1 (pt) |
RU (1) | RU2020133451A (pt) |
SG (1) | SG11202008696RA (pt) |
WO (1) | WO2019175113A1 (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021095599A1 (ja) * | 2019-11-13 | 2021-05-20 | 国立大学法人京都大学 | Pd-1シグナル阻害剤の併用療法 |
IT202000007153A1 (it) * | 2020-04-03 | 2021-10-03 | Ifom Fondazione St Firc Di Oncologia Molecolare | Apporto calorico ridotto e immunoterapia per il trattamento del cancro |
CN114053230B (zh) * | 2021-12-09 | 2023-01-24 | 苏州百迈生物医药有限公司 | 一种表柔比星复方制剂及其制备方法和应用 |
AU2022280511A1 (en) * | 2021-05-28 | 2023-12-14 | Nippon Kayaku Kabushiki Kaisha | Combined use of ubenimex and immune checkpoint inhibitor |
WO2023288299A1 (en) * | 2021-07-15 | 2023-01-19 | Farber Partners, Llc | Use of methanol and prodrugs thereof in therapy |
CN115590187A (zh) * | 2021-10-08 | 2023-01-13 | 南京纽邦生物科技有限公司(Cn) | 通过施用二氢小檗碱模拟热量限制的生物学益处的方法和组合物 |
EP4197525A1 (en) * | 2021-12-20 | 2023-06-21 | Scandion Oncology A/S | Combination of drugs for the treatment of cancer |
CN115531555B (zh) * | 2022-08-19 | 2024-02-09 | 上海市第一人民医院 | 一种甘露糖修饰的纳米颗粒在制备治疗骨肉瘤药物中的应用 |
CN115282147A (zh) * | 2022-08-31 | 2022-11-04 | 深圳市宝安区人民医院 | 罗拉匹坦或/和罗拉匹坦衍生物在抗结核分枝杆菌药物中的应用 |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
GB9209628D0 (en) | 1992-05-05 | 1992-06-17 | Smithkline Beecham Plc | Compounds |
US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
WO1998042752A1 (en) | 1997-03-21 | 1998-10-01 | Brigham And Women's Hospital Inc. | Immunotherapeutic ctla-4 binding peptides |
US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
IL143797A0 (en) | 1998-12-23 | 2002-04-21 | Pfizer | Human monoclonal antibodies to cytotoxic t lymphocyte antigen 4 |
EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
WO2001014424A2 (en) | 1999-08-24 | 2001-03-01 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
US6414002B1 (en) | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
US7034121B2 (en) | 2000-01-27 | 2006-04-25 | Genetics Institue, Llc | Antibodies against CTLA4 |
US7219016B2 (en) | 2001-04-20 | 2007-05-15 | Yale University | Systems and methods for automated analysis of cells and tissues |
NZ568769A (en) | 2002-10-17 | 2010-04-30 | Genmab As | Human monoclonal antibodies against CD20 |
UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
GB0229734D0 (en) | 2002-12-23 | 2003-01-29 | Qinetiq Ltd | Grading oestrogen and progesterone receptors expression |
US7488802B2 (en) | 2002-12-23 | 2009-02-10 | Wyeth | Antibodies against PD-1 |
US7257268B2 (en) | 2003-02-28 | 2007-08-14 | Aperio Technologies, Inc. | Systems and methods for image pattern recognition |
CA3151350A1 (en) | 2005-05-09 | 2006-11-16 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
EA019344B1 (ru) | 2005-07-01 | 2014-03-31 | МЕДАРЕКС, Эл.Эл.Си. | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения |
DK2134689T3 (da) | 2007-03-16 | 2014-06-30 | Scripps Research Inst | Inhibitorer af fokal adhæsionskinase |
JP4782239B2 (ja) | 2007-04-18 | 2011-09-28 | ファイザー・プロダクツ・インク | 異常細胞増殖治療のためのスルホニルアミド誘導体 |
US8023714B2 (en) | 2007-06-06 | 2011-09-20 | Aperio Technologies, Inc. | System and method for assessing image interpretability in anatomic pathology |
JP2011512332A (ja) | 2008-02-11 | 2011-04-21 | キュアー テック リミテッド | 腫瘍治療のためのモノクローナル抗体 |
WO2009105498A1 (en) | 2008-02-19 | 2009-08-27 | Smithkline Beecham Corporation | Anilinopyridines as inhibitors of fak |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
CA2726508C (en) | 2008-06-17 | 2016-06-07 | Astrazeneca Ab | Pyridine compounds |
CN102203132A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂的组合物和使用方法 |
CN102203125A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂及其使用方法 |
JP5551702B2 (ja) | 2008-09-16 | 2014-07-16 | ヒストロックス,インコーポレイテッド. | バイオマーカー発現の再現性のある定量 |
JO3067B1 (ar) | 2008-10-27 | 2017-03-15 | Glaxosmithkline Llc | بيرميدينات بيرازولو امينو كمثبطات ل fak |
US20140155410A1 (en) | 2008-10-27 | 2014-06-05 | Glaxosmithkline Llc | Pyrazolylaminopyridines as inhibitors of fak |
US20100120727A1 (en) * | 2008-11-12 | 2010-05-13 | Kyphia Pharmaceuticals, Inc. | Eflornithine Prodrugs, Conjugates and Salts, and Methods of Use Thereof |
MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
US8647623B2 (en) | 2009-04-10 | 2014-02-11 | Kyowa Hakko Kirin Co., Ltd | Method for treatment of blood tumor using anti-TIM-3 antibody |
US8345509B2 (en) | 2009-04-16 | 2013-01-01 | Chevron U.S.A., Inc. | System and method to create three-dimensional images of non-linear acoustic properties in a region remote from a borehole |
US20110111435A1 (en) | 2009-11-06 | 2011-05-12 | SlidePath Limited | Detecting Cell Surface Markers |
LT3279215T (lt) | 2009-11-24 | 2020-04-10 | Medimmune Limited | Tiksliniai surišantys agentai prieš b7-h1 |
WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
ES2682078T3 (es) | 2010-06-11 | 2018-09-18 | Kyowa Hakko Kirin Co., Ltd. | Anticuerpo anti-TIM-3 |
JP5977761B2 (ja) | 2011-01-25 | 2016-08-24 | シエル・インターナシヨネイル・リサーチ・マーチヤツピイ・ベー・ウイShell Internationale Research Maatschappij Besloten Vennootshap | ガス化反応器 |
US8841418B2 (en) | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
WO2013079174A1 (en) | 2011-11-28 | 2013-06-06 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
MX2015011374A (es) | 2013-03-15 | 2016-01-15 | Squibb Bristol Myers Co | Inhibidores de indolamina 2,3-dioxigenasa (ido). |
US20160194295A1 (en) | 2013-09-06 | 2016-07-07 | Aurigene Discovery Technologies Limited | 1,3,4-Oxadiazole and 1,3,4-Thiadiazole Derivatives as Immunomodulators |
MY186438A (en) | 2013-09-06 | 2021-07-22 | Aurigene Discovery Tech Ltd | 1, 2, 4-oxadiazole derivatives as immunomodulators |
US20160250249A1 (en) * | 2013-10-03 | 2016-09-01 | Inserm ( Institute National De Lasanté Et De La Re Cherche Médicale) | Methods and pharmaceutical compositions for modulating autophagy in a subject in need thereof |
CN108289892B (zh) * | 2015-06-29 | 2021-11-23 | 维瑞斯特姆股份有限公司 | 治疗组合物、组合和使用方法 |
-
2019
- 2019-03-11 BR BR112020018585A patent/BR112020018585A8/pt unknown
- 2019-03-11 CA CA3093742A patent/CA3093742A1/en active Pending
- 2019-03-11 JP JP2020572608A patent/JP2021517589A/ja active Pending
- 2019-03-11 US US16/980,003 patent/US20210030703A1/en active Pending
- 2019-03-11 EP EP19716299.3A patent/EP3765085A1/en active Pending
- 2019-03-11 SG SG11202008696RA patent/SG11202008696RA/en unknown
- 2019-03-11 KR KR1020207028067A patent/KR20210004966A/ko unknown
- 2019-03-11 WO PCT/EP2019/056041 patent/WO2019175113A1/en unknown
- 2019-03-11 RU RU2020133451A patent/RU2020133451A/ru unknown
- 2019-03-11 CN CN201980031861.7A patent/CN112218658A/zh active Pending
- 2019-03-11 AU AU2019236402A patent/AU2019236402A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3093742A1 (en) | 2019-09-19 |
KR20210004966A (ko) | 2021-01-13 |
JP2021517589A (ja) | 2021-07-26 |
RU2020133451A (ru) | 2022-04-12 |
BR112020018585A2 (pt) | 2020-12-29 |
EP3765085A1 (en) | 2021-01-20 |
AU2019236402A1 (en) | 2020-10-01 |
CN112218658A (zh) | 2021-01-12 |
WO2019175113A1 (en) | 2019-09-19 |
US20210030703A1 (en) | 2021-02-04 |
SG11202008696RA (en) | 2020-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112020018585A8 (pt) | Uso de mimeticos de restrição calórica para potencializar a quimioimunoterapia para o tratamento de câncer | |
CY1123177T1 (el) | Ρυθμιστης υποδοχεα ανδρογονου και χρησεις αυτου σε συνδυασμο με οξεικη αμπιρατερονη και πρεδνιζονη για τη θεραπεια καρκινου του προστατη | |
CY1121246T1 (el) | Συζευγμα αντισωματος αντι-trop2-φαρμακου | |
CY1123369T1 (el) | Συνθεσεις και μεθοδοι για τη ρυθμιση της εκφρασης της απολιποπρωτεϊνης (α) | |
CY1118899T1 (el) | Ενωσεις ενεδιυνης, συζευγματα εξ’ αυτων, και χρησεις και μεθοδοι δια τουτων | |
CO2019013020A2 (es) | Anticuerpo anti-cdh6 y conjugado farmaco-anticuerpo anticdh6 | |
BR112019000071A2 (pt) | conjugados adjuvantes de anticorpo | |
CL2018002787A1 (es) | Compuestos de aminopurina sustituida, composiciones de estos y métodos de tratamiento con estos. | |
BR112018002033A2 (pt) | ligantes covalentes em conjugados de anticorpo-fármaco e métodos para fabricação e uso dos mes-mos | |
BR112015032690A2 (pt) | uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir crescimento tumoral e metástases | |
BR112018006448A2 (pt) | derivado de oxaespiro, método de preparação dos mesmos, e aplicações dos mesmos em medicamentos | |
BR112019005305A2 (pt) | compostos espirocíclicos | |
CL2018002699A1 (es) | Profármacos de fármacos citotóxicos que tienen grupos enzimáticamente escindibles. | |
BR112018011261A2 (pt) | ?métodos para tratar câncer, para inibir a proliferação de um tumor e para iniciar, intensificar ou prolongar os efeitos de um inibidor de ponto de verificação ou permitir a um indivíduo responder a um inibidor de pontos de verificação? | |
BR112016028835A2 (pt) | derivados de auristatina e conjugados dos mesmos | |
BR112016000489A8 (pt) | composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos | |
MX366503B (es) | Derivados de amatoxina. | |
BR112021022514A2 (pt) | Conjugados de anticorpo e fármaco | |
BR112015026247A8 (pt) | composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit | |
MX2020006010A (es) | Conjugados de anticuerpo anti-cd22-maitansina, combinaciones y metodos de uso de los mismos. | |
BR112019024719A2 (pt) | Composições e métodos para resposta imunológica antitumor aprimorada | |
BR112023006364A2 (pt) | Terapia de combinação de imuno-oncologia com conjugados de il-2 e pembrolizumabe | |
BR112018068684A2 (pt) | uso de resinas modificadas com ácidos graxos para conferir propriedade antidedadas a uma folha de vidro | |
MX2020004836A (es) | Agentes anticancerígenos. | |
BR112017021194A2 (pt) | compostos espirocíclicos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B25G | Requested change of headquarter approved |
Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) ; UNIVERSITE DE PARIS (FR) ; SORBONNE UNIVERSITE (FR) ; ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP) (FR) ; UNIVERSITE PARIS-SACLAY (FR) |
|
B25D | Requested change of name of applicant approved |
Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) ; SORBONNE UNIVERSITE (FR) ; ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP) (FR) ; UNIVERSITE PARIS-SACLAY (FR) ; UNIVERSITE PARIS CITE (FR) |